Study #2021-0911
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC .
MD Anderson Study Status
Enrolling
Treatment Agent
177Lu girentuximab, Nivolumab, Cabozantinib, ArabinoFuranosylGuanine [18F]F-AraG
Description
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Study phase:
Physician name:
Eric Jonasch
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-833-767-1887
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.